Reference health
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers
30/30 checkable references clean · checked 2026-07-24
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
The 30 checked references that resolve
resolves10.1021/bi0003442
Base Excision Repair Is Impaired in Mammalian Cells Lacking Poly(ADP-ribose) Polymerase-1
resolves10.1158/0008-5472.CAN-06-0140
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
resolves10.1038/sj.onc.1209874
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
resolves10.1086/345310
Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene
resolves10.1038/nature03445
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
resolves10.1038/nature03443
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
resolves10.1200/JCO.2008.16.0812
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
resolves10.1101/sqb.2005.70.012
Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer
resolves10.1158/1078-0432.CCR-07-4953
Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
resolves10.1021/jm8001263
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2<i>H</i>-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
resolves10.1093/jnci/89.15.1138
Accelerated Titration Designs for Phase I Clinical Trials in Oncology
resolves10.1038/sj.bjc.6602558
Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies
resolves10.1093/jnci/djh081
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors
(Ovarian Cancer)
resolves10.1200/JCO.1999.17.11.3461
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
resolves10.1186/1471-2407-8-17
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
resolves10.1038/nature06633
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-24 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1056/nejmoa0900212"><img src="https://citestamp.com/citestamped/10.1056/nejmoa0900212/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1056/nejmoa0900212)